Inclusion Criteria:  Age 18-70 years old, no gender and race limited; Estimated life expectancy > 12 weeks deemed by investigator； CD22 were positive by histopathology and/or cytology diagnosis； Patients with relapsed and/or refractory non-Hodgkin's B cell lymphoma (r/r B-NHL)； Relevant indicators for disease or assessment within 4 weeks after the last treatment; Quality of Life Score (KPS) >50%； Subject has adequate organ function at screening, cardiac ejection fraction ≥ 40%, no evidence of pericardial effusion as determined by an echocardiogram (ECHO); serum ALT/ AST <3 upper limit of normal (ULN); bilirubin<2.0 mg/dl; serum creatinine ≤1.6 mg/dl and/or BUN ≤ 1.5 mg/dl; No remission or relapse after hematopoietic stem cell transplantation or autologous somatic immunotherapy; Unsuitable conditions for stem cell transplantation; Signed informed consent form (ICF).  Exclusion Criteria:  Women in pregnancy or lactation; In active infection including hepatitis B, hepatitis C, HIV, or other fatal viral and bacterial infection； The absolute count of nonprimary neutrophil < 0.75×10^9/L or platelet count < 50×10^9/L; Abnormal vital signs and failure to cooperate with examination; Patients with mental or psychological diseases who cannot cooperate with treatment and efficacy evaluation; Highly allergic constitution or history of severe allergy; Patients with systemic infection or severe local infection requiring anti-infection treatment; Patients with severe autoimmune diseases; Presence of any other conditions that are unsuitable for this study as judged by the investigator.